ALNY

Q: What is the price of Alnylam Pharmaceuticals (ALNY) today?

The price of Alnylam Pharmaceuticals (ALNY) today is $ 325.07, with return of 31.74% compared to the last year. The price of Alnylam Pharmaceuticals (ALNY) started the year trading around $ 397.65 and today it is at $ 325.07. Follow the real-time price chart, the historical price of Alnylam Pharmaceuticals (ALNY) and international markets.

Q: When does Alnylam Pharmaceuticals (ALNY) pay dividends?

Alnylam Pharmaceuticals (ALNY) did not distribute dividends in the last year.

Q: Is Alnylam Pharmaceuticals (ALNY) worth it?

Currently, Alnylam Pharmaceuticals (ALNY) is priced at $ 325.07, with a P/E of 140.07%, representing a deviation of -1,242% from its historical average P/E. In the last year, the stock showed a variation of 31.74 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 31.74%.It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Q: How can I buy Alnylam Pharmaceuticals (ALNY) stock?

Investing in stocks of Alnylam Pharmaceuticals (ALNY) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

Q: How much would 100 shares of Alnylam Pharmaceuticals (ALNY) yield today?

The yield of Alnylam Pharmaceuticals (ALNY) was -3.84% in the last month, 31.74% in the last year and 136.64% in the last 5 years (already considering appreciation and dividends).In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.If you wanted to buy 100 stocks of Alnylam Pharmaceuticals (ALNY) today, the total investment would be $ 32,507.00, based on the current price of $ 325.07.If past performance were to repeat, the return on your investment would be:In 1 year: $ 42,824.72In 5 years: $ 76,924.56In 10 years: $ 175,853.12It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

Alnylam Pharmaceuticals Inc.

Price

$ 325.07

return (12m)

31.74%

p/e

140.07

p/b

55.68

DIVIDEND YIELD

0.00%

price ALNY

ALNY

If you had invested

years ago

7 days

30 days

6 months

YTD

1 year

5 years

10 years

ago, you would now have *

ago, you would now have:

*The figure considers the reinvestment of dividends.

Return of ALNY

1 month

3 months

1 year

2 years

5 years

10 years

return

1 month

-3.84%

3 months

-30.08%

1 year

31.74%

2 years

116.66%

5 years

136.64%

10 years

440.97%

Fundamentals ALNY

review the fundamentals of Alnylam Pharmaceuticals shares

P/E

140.07

Sector: -3.72 Industry: -3.72

P/S (Price-to-Sales)

11.83

Sector: -3.83 Industry: -3.83

P/B

55.68

Sector: 1.99 Industry: 1.99

DIVIDEND YIELD (DY)

0.00%

Sector: - Industry: -

ROA

6.32%

Sector: -64.61% Industry: -64.61%

ROE

39.76%

Sector: -66.34% Industry: -66.34%

ROIC

40.12%

Sector: -1,293.53% Industry: -1,293.53%

NET MARGIN

8.45%

Sector: -40.94% Industry: -40.94%

GROSS MARGIN

81.64%

Sector: 39.00% Industry: 39.00%

OPERATING MARGIN

13.51%

Sector: -40.81% Industry: -40.81%

EV/EBITDA

69.60

Sector: -3.76 Industry: -3.76

EV/EBIT

76.32

Sector: -3.91 Industry: -3.91

PRICE-TO-ASSETS

8.85

Sector: 1.45 Industry: 1.45

BVPS

5.98

Sector: 1.76 Industry: 1.76

EPS

2.38

Sector: -2.03 Industry: -2.03

EQUITY-TO-ASSETS RATIO

0.16

Sector: 0.40 Industry: 0.40

LIABILITIES / ASSETS

0.84

Sector: 0.40 Industry: 0.40

CAGR REVENUE 5 YEARS

34.48%

Sector: - Industry: -

CAGR PROFIT 5 YEARS

0.00%

Sector: - Industry: -

FAIR VALUE OF Alnylam Pharmaceuticals ASSETS ACCORDING TO BENJAMIN GRAHAM

Graham's Fair Value

The Fair Value formula was created by Benjamin Graham to identify stocks with appreciation potential or that are being traded for less than they are worth. Graham was one of the greatest investors in history and Warren Buffet's mentor.

Current price

$ 325.07

Fair Value

$ 0.00

Upside Return potential.

-94.50%

See Graham's ranking

Because it considers equity value in its calculation, the formula does not work well for technology companies.

This is not a buy/sell recommendation; the fair value calculation takes into account only the formula created by Benjamin Graham, published in the book The Intelligent Investor.

Fundamentals ALNY

DRAG THE FRAME TO SEE MORE DATA

Stock Comparison Tool

DRAG THE FRAME TO SEE MORE DATA

	p/e	p/b	ROE	dy	market cap	net margin
JNJ	22.33	7.55	33.81%	2.07%	$ 598.47 B	28.46%
PFE	20.23	1.69	8.35%	6.22%	$ 157.22 B	12.42%
ABBV	97.04	0.00	0.00%	2.87%	$ 410.09 B	6.91%
NVO	10.62	5.47	51.50%	4.51%	$ 166.32 B	33.05%
MRK	16.84	0.00	0.00%	2.65%	$ 307.32 B	28.08%
AZN	31.62	6.64	20.99%	1.50%	$ 323.31 B	17.41%
GILD	21.74	8.18	37.62%	2.12%	$ 185.00 B	28.90%
BMY	18.00	-3.73	-20.72%	3.99%	$ 126.99 B	14.64%
ZTS	21.48	17.24	80.25%	1.53%	$ 57.42 B	28.23%
REGN	17.87	2.58	14.41%	0.45%	$ 80.51 B	31.41%
HALO	25.89	168.09	649.21%	0.00%	$ 8.20 B	22.69%
AMGN	27.13	24.16	89.06%	2.45%	$ 209.22 B	20.98%
MCK	27.98	-1,226.73	-4,383.84%	0.31%	$ 121.45 B	1.09%
VRTX	31.92	6.76	21.18%	0.00%	$ 126.19 B	32.94%
CAH	32.55	-20.04	-61.56%	0.89%	$ 54.10 B	0.68%
ADMA	17.77	8.63	48.57%	0.00%	$ 3.72 B	42.87%
BIIB	21.81	1.54	7.08%	0.00%	$ 28.20 B	13.07%
HRMY	8.91	1.98	22.24%	0.00%	$ 1.66 B	22.48%

Stock vs Index Comparison Tool

If you had invested (change) 2 years years ago, ago, you would now have

R$ 1.000,00 in PETR4 You would now have R$ 2.294,60

R$ 1.000,00 in LEVE3 You would now have R$ 5.240,60

*The value considers the reinvestment of dividends.

ALNY Historical Dividends

current DY: 0.00%

5-year average DY: 0.00%

no dividend paid in the period.

ABOUT THE COMPANY Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Inc.

Average user rating I10

4.0 (7 people)

United States

23 years

Founded: 2003

2004

Time since IPO - 22 years

1.453

Employees

The Company Alnylam Pharmaceuticals Inc. (United States), is listed on Nasdaq with a market value of $ 43.95 Billions, having an equity of $ 789.18 Millions.

With a total of 1.453 employees, the company is listed in the sector of Health Care and categorized in industry of Biotechnology.

In the last 12 months the Company had a revenue of $ 3.71 Billions, which generated a profit in the amount of $ 313.74 Millions.

As for its main indicators, the Company has a P/E ratio of 140.07, a P/BV ratio of 55.68 and in the last 12 months the Company did not pay dividends.

The Company is traded internationally through the ticker ALNY.

Market cap

$ 43.95 Billions

Net worth

$ 789.18 Millions

US$ 789,180,000.00

Assets

$ 4.97 Billions

US$ 4,966,330,000.00

Total Shares Outstanding

132.00 Millions

132,000,000

Average Daily Trading Volume

$ 1.61 Million

US$ 1,606,392.00

Sector

Health Care

Industry

Biotechnology

ALNY

businesses that generate revenue for Alnylam Pharmaceuticals

Regions where Alnylam Pharmaceuticals generates revenue

ALNY revenue and profits

Financial Results ALNY

DRAG THE FRAME TO SEE MORE DATA

ALNY cash flow

DRAG THE FRAME TO SEE MORE DATA

Discover more stocks

BFRA - Biofrontera

$ - -0,00% (12M)

P/E

0.00

0.00%

ROE

-893.55%

P/B

0.00

MCK - McKesson

$ 990.95 54,53% (12M)

P/E

27.98

0.31%

ROE

-4,383.84%

P/B

-1,226.73

CAH - Cardinal Health

$ 229.88 80,59% (12M)

P/E

32.55

0.89%

ROE

-61.56%

P/B

-20.04

JNJ - Johnson & Johnson

$ 248.56 52,73% (12M)

P/E

22.33

2.07%

ROE

33.81%

P/B

7.55

PFE - Pfizer

$ 27.26 13,23% (12M)

P/E

20.23

6.22%

ROE

8.35%

P/B

1.69

ABBV - AbbVie

$ 234.26 15,35% (12M)

P/E

97.04

2.87%

ROE

0.00%

P/B

0.00

MRK - Merck & Co.

$ 121.41 36,18% (12M)

P/E

16.84

2.65%

ROE

0.00%

P/B

0.00

AZN - AstraZeneca

$ 203.73 38,15% (12M)

P/E

31.62

1.50%

ROE

20.99%

P/B

6.64

BFRA - Biofrontera

$ - -0,00% (12 M)

P/L

0.00

0.00%

ROE

-893.55%

P/VP

0.00

MCK - McKesson

$ 990.95 54,53% (12 M)

P/L

27.98

0.31%

ROE

-4,383.84%

P/VP

-1,226.73

CAH - Cardinal Health

$ 229.88 80,59% (12 M)

P/L

32.55

0.89%

ROE

-61.56%

P/VP

-20.04

JNJ - Johnson & Johnson

$ 248.56 52,73% (12 M)

P/L

22.33

2.07%

ROE

33.81%

P/VP

7.55

PFE - Pfizer

$ 27.26 13,23% (12 M)

P/L

20.23

6.22%

ROE

8.35%

P/VP

1.69

ABBV - AbbVie

$ 234.26 15,35% (12 M)

P/L

97.04

2.87%

ROE

0.00%

P/VP

0.00

MRK - Merck & Co.

$ 121.41 36,18% (12 M)

P/L

16.84

2.65%

ROE

0.00%

P/VP

0.00

AZN - AstraZeneca

$ 203.73 38,15% (12 M)

P/L

31.62

1.50%

ROE

20.99%

P/VP

6.64

Frequently Asked Questions

What is the price of Alnylam Pharmaceuticals (ALNY) today?

The price of Alnylam Pharmaceuticals (ALNY) today is $ 325.07, with return of 31.74% compared to the last year. The price of Alnylam Pharmaceuticals (ALNY) started the year trading around $ 397.65 and today it is at $ 325.07. Follow the real-time price chart, the historical price of Alnylam Pharmaceuticals (ALNY) and international markets.

When does Alnylam Pharmaceuticals (ALNY) pay dividends?

Alnylam Pharmaceuticals (ALNY) did not distribute dividends in the last year.

Is Alnylam Pharmaceuticals (ALNY) worth it?

Currently, Alnylam Pharmaceuticals (ALNY) is priced at $ 325.07, with a P/E of 140.07%, representing a deviation of -1,242% from its historical average P/E. In the last year, the stock showed a variation of 31.74 in its price and distributed $ 0.00 in dividends, resulting in a Dividend Yield of 0.00%. The total shareholder return was 31.74%.

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

How can I buy Alnylam Pharmaceuticals (ALNY) stock?

Investing in stocks of Alnylam Pharmaceuticals (ALNY) can be done in two ways: by buying the stock abroad. The stock is the original stock, traded on international exchanges. By buying it, you invest with money outside Brazil, which brings greater geographical and currency diversification.

BDR is a receipt for that stock, traded on the B3 with reais, through a brazilian brokerage. Although the money remains in Brazil, the BDR still offers diversification, as it represents a foreign company and is linked to the dollar.

How much would 100 shares of Alnylam Pharmaceuticals (ALNY) yield today?

The yield of Alnylam Pharmaceuticals (ALNY) was -3.84% in the last month, 31.74% in the last year and 136.64% in the last 5 years (already considering appreciation and dividends).

In the last 12 months, the company paid a total of $ 0.00 in dividends, with a Dividend Yield of 0.00%.

If you wanted to buy 100 stocks of Alnylam Pharmaceuticals (ALNY) today, the total investment would be $ 32,507.00, based on the current price of $ 325.07.

If past performance were to repeat, the return on your investment would be:

In 1 year: $ 42,824.72
In 5 years: $ 76,924.56
In 10 years: $ 175,853.12

It is important to remember that past performance does not guarantee future results. This should not be seen as an investment recommendation.

ALNY

Alnylam Pharmaceuticals Inc.

Price

return (12m)

p/e

p/b

DIVIDEND YIELD

Return of ALNY

review the fundamentals of Alnylam Pharmaceuticals shares

P/E

P/S (Price-to-Sales)

P/B

DIVIDEND YIELD (DY)

ROA

ROE

ROIC

NET MARGIN

GROSS MARGIN

OPERATING MARGIN

EV/EBITDA

EV/EBIT

PRICE-TO-ASSETS

BVPS

EPS

EQUITY-TO-ASSETS RATIO

LIABILITIES / ASSETS

CAGR REVENUE 5 YEARS

CAGR PROFIT 5 YEARS

Graham's Fair Value

If you had invested (change) 2 years years ago, ago, you would now have

current DY: 0.00%

5-year average DY: 0.00%

ABOUT THE COMPANY Alnylam Pharmaceuticals

Alnylam Pharmaceuticals Inc.

United States

23 years

2004

1.453

PROFIT X PRICE ALNY

Financial Results ALNY

ALNY cash flow

asset growth - ALNY

ALNY balance sheet

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

BFRA - Biofrontera

MCK - McKesson

CAH - Cardinal Health

JNJ - Johnson & Johnson

PFE - Pfizer

ABBV - AbbVie

MRK - Merck & Co.

AZN - AstraZeneca

Frequently Asked Questions